Clinical Trial Search

Primary: Phase 1b/2 : Overall Response Rate of Number of Participants — 7; 8 Participants

Primary: Percentage of Participants With Remission at Week 8 — 13.3; 23.1; 14.3; 19.5 percentage of participants — p=0.76

Primary: Number of Participants With All-Cause Mortality in the Intent-to-Treat (ITT) Population — 103; 95 Participants

Primary: Mean Change of Proteinuria as Measured by Spot Urine Protein/Creatinine Ratio (sPCR) at Week 24 — -157.5; -577.2; -177.4 mg/g — p=0.97

Primary: Change in Fat Consumption (During VeNS) — 50.23; 54.44 % of fat as metabolic substrate

Primary: Confirmed Overall Response Rate Per the RECIST 1.1 Criteria — 0 percentage of patients

Primary: Number of Participants With Vaginal or Urinary Symptoms After Surgery, Assessed by Validated Questionnaire (Modified PRO-CTCAE) — 4; 11; 8; 25 Participants

Primary: Percentage of Participants With Remission at Week 8 — 4.3; 0.0; 2.5; 13.3 percentage of participants — p=0.021

Primary: Contact Force Through Measurement of Force-time Integral (FTI) — 471; 571 gm/s

Primary: Factor Analysis & PROMIS Correlation for Samples 2 & 3 — NA; .990; NA; NA Pearson Coefficients

Primary: Percentage of Participants Responding to Hepatitis B Surface Antigen (HBsAg) — 70.16; 82.01; 65.75; 83.68 Percentage of Participants

Primary: Number of Subjects With a Complete or Partial Response to Treatment — 8 Participants

Primary: Number of Participants Who Experienced Treatment-Emergent Adverse Events (TEAEs), Treatment-Emergent Serious Adverse Events (SAEs), and Any Grade ≥ 1 Laboratory…

Primary: Ocular Physiology — 0.76; 0.79; 0.78; 0.63 units on a scale

Primary: Triglyceride Concentration (Percent Change From Baseline) — -40; -2 percent change from baseline